Nausea and vomiting · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in adverse event (nausea/ vomiting) compared with observation alone (low certainty).
1 finding from 1 review
Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in overall survival compared with observation alone (low certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon showed no clear difference in progression‐free survival compared with observation alone (low certainty).
1 finding from 1 review
Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon may leads to higher adverse event (flu‐like symptoms) compared with observation alone (low certainty).
1 finding from 1 review
Adverse effect: fatigue · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon may leads to higher adverse event (fatigue) compared with observation alone (low certainty).
1 finding from 1 review
Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (flu‐like symptoms) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effect: fatigue · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (fatigue) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Neurotoxicity · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (neurotoxicity) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Interferon + SSA (2 RCTs; 171 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes interferon + SSA (2 RCTs; 468 participants) compared with placebo (very low certainty).
4 findings from 1 review
HR 0.34 [0.14, 0.8]
2 studies · 468 participants
Very low
OR 5.71 [1.9, 17.2]
4 studies · 283 participants
Very low
HR 0.23 [0.06, 0.93]
3 studies · 512 participants
Very low
Show 1 more finding
Interferon (1 RCT; 66 participants)
It is very uncertain whether estimates of effects, ranking, and certainty of evidence for… changes interferon (1 RCT; 66 participants) compared with placebo (very low certainty).
4 findings from 1 review
HR 0.41 [0.18, 0.94]
1 study · 66 participants
Very low
OR 4.03 [0.86, 18.8]
2 studies · 86 participants
Very low
HR 0.27 [0.07, 1.1]
1 study · 66 participants
Very low
Show 1 more finding